Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679916 | 1.00 | ALOX5 (0.47) | ALOX5PTGS2PDE4APDE4BPDE4C | |
| SCHEMBL1100031 | 0.87 | ALDH1A1 (0.46) | PDE4APDE4BPDE4CPDE4DFNTA | |
| SCHEMBL3833937 | 0.84 | PDE4A (0.48) | ALOX5PTGS2PDE4APDE4BPDE4C | |
| SCHEMBL8798071 | 0.84 | ALOX5 (0.47) | ALOX5PTGS2ALOX15ALOX12CALM1 | |
| SCHEMBL8797818 | 0.82 | ALOX5 (0.46) | ALOX5PTGS2ALOX15ALOX12CALM1 | |
| SCHEMBL7131334 | 0.81 | ALDH1A1 (0.43) | PDE4APDE4BPDE4CPDE4DFNTA | |
| SCHEMBL1119249 | 0.80 | ALOX5 (0.54) | ALOX5PTGS2ALOX15ALOX12CA1 | |
| SCHEMBL3927720 | 0.80 | MAPT (0.46) | PDE4APDE4BPDE4CPDE4DALOX15 | |
| SCHEMBL11621614 | 0.78 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DFNTA | |
| SCHEMBL12404016 | 0.78 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0542671-B1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA GEIGY AG (CH) | 1997-01-02 | — | — | EP | claimed |
| EP-0542671-A1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| JP-5213808-A | — | — | None | — | — | JP | disclosed |
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIOVENTURES, INC., | 2025-07-10 | — | — | US | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-5693807-A | Substituted hydroquinone derivatives | CIBA-GEIGY CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0542671-B1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA GEIGY AG (CH) | 1997-01-02 | — | — | EP | disclosed |
| US-5290939-A | Process for the manufacture of brofaromine and analogs thereof | CIBA-GEIGY CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| JP-H05213808-A | SUBSTITUTED HYDROQUINONE DERIVATIVE | CIBA GEIGY AG | 1993-08-24 | — | — | JP | disclosed |
| EP-0542671-A1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | TEAD1, TEAD2, TEAD3 | ALOX5 2747/4885PTGS2 1400/4885PDE4A 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.